Algernon Pharmaceuticals is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
While other research is exploring DMT for its hallucinogenic qualities and effects, Algernon will be working to unlock DMT’s non-psychedelic potential to help promote healing and recovery in the brain from a stroke, one of the most devastating injuries a human being can experience.
Stock Performance
Algernon Pharmaceuticals News 55 articles
- Algernon to Acquire NoBrainer Imaging Centers, Inc. – Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
- Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
- Netcapital to Host Planned Reg A Offering by Algernon NeuroScience
- Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
- Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
- Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
- Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
- Algernon Pharmaceuticals Announces Closing of Private Placement
- Algernon Pharmaceuticals Announces Increase to Private Placement
- Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
- Algernon Pharmaceuticals Announces Private Placement
- Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
- Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
- Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research’s Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
- Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
- Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
- Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
- Algernon Pharmaceuticals Announces Closing of Private Placement
- Algernon Pharmaceuticals Announces Increase to Private Placement
- Algernon Pharmaceuticals Announces Private Placement
- Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
- Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
- Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
- Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
- Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
- Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
- Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
- Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
- Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
- Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
- Algernon Pharmaceuticals Announces Closing of Rights Offering
- Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
- Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
- Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
- Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
- Algernon Pharmaceuticals Announces Launch of Rights Offering
- Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
- Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split
- Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor
- Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
Showing the 40 most recent of 55 articles.